Breast Cancer Clinical Trials
Clinical trials give patients access to new therapies and protocols under investigation here and around the country that could become tomorrow's gold standard treatment.
The Cancer Center at BIDMC is an important center of research into the safety and effectiveness of new cancer therapies. Your physician will help you evaluate whether participation in a clinical trial is appropriate for you.
The following clinical trials related to Breast Cancer are now available through BIDMC. Please email or call Arline Broberg at 617-667-3060 if you have questions about participating in a clinical trial.
- A Phase II Trial of Cabozantinib in Women with Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone - Learn More.
- Phase I study of the oral PI3kinase inhibitor BKM120 and the oral PARP inhibitor olaparib in patients with recurrent triple negative breast cancer or high grade serous ovarian cancer - Learn More.
- A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations - Learn More.
- A randomized phase II study of preoperative cisplatin versus paclitaxel in patients with triple negative breast cancer without germline BRCA mutations: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker - Learn More.
- A randomized Phase II study of Trastuzumab emtansine (T-DM1) vs Paclitaxel in combinaton with Trastuzumab for Stage I HER2-positive breast cancer - Learn More.
- The impact of HER2 heterogeneity on the treatment of early-stage HER2-positive breast cancer: a phase II study of T-DM1 in combination with Pertuzumab in the preoperative setting - Learn More.
- A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy - Learn More.
- A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer. - Learn More.
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone). A Prospective, Single-Arm Cohort Study of Patients Receiving Endocrine Therapy Alone (No Radiotherapy) after Breast Conserving Surgery for Early-Stage, Post-Menopausal Breast Cancer - Learn More.
- A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (ANTI-PD L1 Antibody) in Combination with NAB-Paclitaxel Compared with Placebo with NAB-Paclitaxel for Patients with Previously Untreated Metastatic Triple-Negative Breast Cancer - Learn More.
- A Phase Ib/II Study of Palbociclib in Combination with Bazedoxifene in Hormone Receptor Positive Breast Cancer - Learn More.
- An Open-Label, Single-Arm Multicenter Phase 1B/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination with Pembrolizumab in Subjects with Metastatic Triple-Negative Breast Cancer (mTNBC) - Learn More.
- A phase II trial of HKI-272 (Neratinib) for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases - Learn More.
- A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer - Learn More.
- A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women - Learn More.
- A Phase II Study of Eribulin Mesylate in Combination with Trastuzumab and Pertuzumab in Women with Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer - Learn More.
- A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician?s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - Learn More.
Back to top
Updated May 2016